Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report

P Horby, WS Lim, J Emberson, M Mafham, J Bell… - MedRxiv, 2020 - medrxiv.org
ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse
lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing …

Dexamethasone in hospitalized patients with Covid-19

RECOVERY Collaborative Group - New England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with diffuse lung
damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby …

Dexamethasone in hospitalized patients with Covid-19-preliminary report

L Chappell, P Horby, WS Lim… - The New England …, 2020 - kclpure.kcl.ac.uk
Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …

Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support

K Crothers, R DeFaccio, J Tate, PR Alba… - European …, 2022 - Eur Respiratory Soc
Background Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19)
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …

Potential adverse effects of dexamethasone therapy on COVID-19 patients: review and recommendations

F Chen, L Hao, S Zhu, X Yang, W Shi, K Zheng… - Infectious diseases and …, 2021 - Springer
In the context of the coronavirus disease 2019 (COVID-19) pandemic, the global healthcare
community has raced to find effective therapeutic agents against severe acute respiratory …

Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 pneumonia: an open-label …

M Taboada, N Rodríguez, PM Varela… - European …, 2022 - Eur Respiratory Soc
Background Low-dose dexamethasone demonstrated clinical improvement in patients with
coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the …

Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled …

J Villar, JM Añón, C Ferrando, G Aguilar, T Muñoz… - Trials, 2020 - Springer
Background There are no specific generally accepted therapies for the coronavirus disease
2019 (COVID-19). The full spectrum of COVID-19 ranges from asymptomatic disease to mild …

Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

F Salton, P Confalonieri, S Centanni… - European …, 2023 - Eur Respiratory Soc
Background Dysregulated systemic inflammation is the primary driver of mortality in severe
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …

Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX …

BM Tomazini, IS Maia, AB Cavalcanti, O Berwanger… - Jama, 2020 - jamanetwork.com
Importance Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019
(COVID-19) is associated with substantial mortality and use of health care resources …

Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial

N Toroghi, L Abbasian, A Nourian… - Pharmacological …, 2022 - Springer
Background and objectives Corticosteroids are commonly used in the treatment of
hospitalized patients with COVID-19. The goals of the present study were to compare the …